Repligen (NASDAQ:RGEN) Announces Earnings Results

Repligen (NASDAQ:RGENGet Free Report) issued its earnings results on Tuesday. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.09, Briefing.com reports. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.92%. The business had revenue of $154.87 million during the quarter, compared to analysts’ expectations of $153.34 million. During the same period in the previous year, the company earned $0.23 earnings per share. The business’s revenue for the quarter was up 9.7% compared to the same quarter last year. Repligen updated its FY24 guidance to $1.50-1.58 EPS and its FY 2024 guidance to 1.500-1.580 EPS.

Repligen Stock Performance

Repligen stock traded down $5.65 during trading on Thursday, reaching $144.82. The company had a trading volume of 106,023 shares, compared to its average volume of 657,329. The firm’s 50-day simple moving average is $141.59 and its 200 day simple moving average is $144.78. Repligen has a 52 week low of $113.50 and a 52 week high of $211.13. The company has a current ratio of 6.65, a quick ratio of 5.56 and a debt-to-equity ratio of 0.26. The firm has a market capitalization of $8.11 billion, a price-to-earnings ratio of -406.66, a price-to-earnings-growth ratio of 4.27 and a beta of 0.96.

Insiders Place Their Bets

In other news, Director Anthony Hunt sold 22,191 shares of Repligen stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the transaction, the director now directly owns 139,840 shares of the company’s stock, valued at $20,328,540.80. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 1.20% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on RGEN. JPMorgan Chase & Co. boosted their price target on Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 31st. Wolfe Research started coverage on shares of Repligen in a research note on Thursday. They set a “peer perform” rating on the stock. Royal Bank of Canada reiterated an “outperform” rating and issued a $205.00 price target on shares of Repligen in a research note on Thursday, September 26th. Wells Fargo & Company began coverage on shares of Repligen in a research report on Tuesday, August 27th. They set an “overweight” rating and a $180.00 price objective on the stock. Finally, Stephens restated an “overweight” rating and issued a $170.00 target price on shares of Repligen in a report on Tuesday, July 30th. Four analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, Repligen has a consensus rating of “Moderate Buy” and a consensus price target of $190.25.

View Our Latest Stock Analysis on RGEN

About Repligen

(Get Free Report)

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Featured Articles

Earnings History for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.